CCMW
SNDX icon

Cypress Capital Management (Wyoming)’s Syndax Pharmaceuticals SNDX Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5
Closed – – 276
2021
Q4 		$0 Hold
5
– – ﹤0.01% 304
2021
Q3 		$0 Sell
5
-76
-94% -$1.27K ﹤0.01% 303
2021
Q2 		$1K Hold
81
– – ﹤0.01% 291
2021
Q1 		$2K Sell
81
-51,349
-100% -$1.16M ﹤0.01% 274
2020
Q4 		$1.14M Buy
+51,430
New +$1.07M 0.99% 33

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s SNDX Position: Q1 2022 in Review

Cypress Capital Management (Wyoming) sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 5 shares.

Cypress Capital Management (Wyoming) first reported a position in SNDX in Q4 2020 and held it in 5 quarters. The position peaked at $1.14M in Q4 2020. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Cypress Capital Management (Wyoming) reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 5 Syndax Pharmaceuticals shares in Q1 2022.
  • Cypress Capital Management (Wyoming) first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Cypress Capital Management (Wyoming)'s Syndax Pharmaceuticals position peaked at $1.14M in Q4 2020.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q1 2022, filed 9 May 2022.